Trends of the Extra-Hepatic Biliary Cancer and Its Surgical Management: A Cross-Sectional Study From the National Cancer Database.

extrahepatic biliary cancers extrahepatic cholangiocarcinoma national cancer database robotic biliary surgery surgical management

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Aug 2022
Historique:
accepted: 29 07 2022
entrez: 5 9 2022
pubmed: 6 9 2022
medline: 6 9 2022
Statut: epublish

Résumé

Introduction Biliary cancers are rare cancers with poor prognoses. In this study, we aimed to evaluate trends in early detection and surgical treatment and approaches in extra-hepatic biliary tract cancers (EBCs) over 13 years in the US. Methods The most recent data on patients diagnosed with EBC between 2004 and 2016 were extracted from the National Cancer Database (NCDB). The patients' demographics (sex, age, race), primary tumor sites, tumor grades and stages, staging modalities, diagnostic confirmation, surgical treatment modalities and approaches, and 90-day mortality were analyzed to determine trends. Results Biopsy was the most common staging modality in 63.9% of total 60,291 patients. The bile duct was the primary tumor site (55.0%). Histologic examination was the most common confirmatory diagnostic modality (77.5%). The most common stage was stage II (23%). The most common surgical treatment modality was radical surgery (13.88%). The open surgical approach was used in 27.1% of patients, followed by a laparoscopic approach (4.3%). Conclusion EBC showed no significant change in the trends of the stage at diagnosis, treatment modality, and extent of surgical procedures despite advances in surgical diagnostic and therapeutic modalities; however, the total number of cases slightly increased between 2004 and 2016.

Identifiants

pubmed: 36059334
doi: 10.7759/cureus.27584
pmc: PMC9428418
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e27584

Informations de copyright

Copyright © 2022, Tuma et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Curr Opin Gastroenterol. 2012 May;28(3):244-52
pubmed: 22274618
Oncology. 2021;99(2):72-83
pubmed: 33147583
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Am Surg. 2019 May 1;85(5):511-517
pubmed: 31126365
Ann Surg Oncol. 2019 Jun;26(6):1604-1612
pubmed: 30737668
Cancers (Basel). 2020 Nov 13;12(11):
pubmed: 33202975
J Hepatol. 2020 Jul;73(1):170-185
pubmed: 32171892
World J Surg. 2014 Dec;38(12):3215-21
pubmed: 25123177
Hepatobiliary Surg Nutr. 2016 Aug;5(4):311-21
pubmed: 27500143
Liver Cancer. 2016 Nov;6(1):59-65
pubmed: 27995089
Int J Surg. 2018 Jun;54(Pt A):156-162
pubmed: 29730072
Ann Thorac Surg. 2019 Feb;107(2):378-385
pubmed: 30312615
Biomed Res Int. 2019 Apr 08;2019:1835085
pubmed: 31080809
Int J Surg. 2020 Nov;83:196-204
pubmed: 32980518
J Hepatol. 2020 Feb;72(2):353-363
pubmed: 31954497
Am Surg. 2017 Jul 1;83(7):679-686
pubmed: 28738935
Gastroenterol Rep (Oxf). 2015 Aug;3(3):209-15
pubmed: 25169922

Auteurs

Faiz Tuma (F)

Surgery, Central Michigan University College of Medicine, Saginaw, USA.
Surgery, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, USA.

Ali Abbaszadeh-Kasbi (A)

Surgery, Mayo Clinic, Jacksonville, USA.

Gitonga Munene (G)

Surgical Oncology, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, USA.

Saad Shebrain (S)

Surgery, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, USA.

William C Durchholz (WC)

Surgery, Central Michigan University College of Medicine, Saginaw, USA.

Classifications MeSH